RE: Daily mail31 Jan 2024 08:10
Clinical trial specialist Hvivo will start paying an annual dividend from this year as it cashes in on rising demand for its services.
The group, which recruits healthy adult volunteers and infects them with a medical-grade version of a virus to test the effectiveness of drugs and vaccines being developed by biotech and pharmaceutical companies, reported that revenues increased 15.5 per cent to £56million in 2023.
In a further dose of good news, Hvivo has already secured 90 per cent of its revenue for this year and expects to make £62million. Shares surged 8.4 per cent, or 2.2p, to 28.5p.